NCT05606159View on ClinicalTrials.gov

Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2024

Conditions
Clostridium Difficile Infection Recurrence
Interventions
DIETARY_SUPPLEMENT

Bacillus velezensis DSM 33864

1 probiotic capsule to be taken orally once a day, with breakfast, once a day for 8 weeks.

DIETARY_SUPPLEMENT

Placebo

1 microcrystalline cellulose-containing placebo capsule to be taken orally once a day with breakfast, for 8 weeks.

Trial Locations (1)

48073

Beaumont Hospital, Royal Oak

Sponsors

Lead Sponsor

Novozymes A/S
All Listed Sponsors
collaborator

Estimates OY

UNKNOWN

lead

Novozymes A/S

INDUSTRY

NCT05606159 - Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections | Biotech Hunter | Biotech Hunter